Skip to content

The Organ Transplant Recipient HPV and Skin Cancer Study

The Organ Transplant Recipient HPV and Skin Cancer Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05284877
Enrollment
1500
Registered
2022-03-17
Start date
2022-03-10
Completion date
2043-03-31
Last updated
2025-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Cervical Intraepithelial Neoplasia, HPV Infection, HPV-Related Malignancy, Skin Cancer, Skin Dysplasia, Solid Organ Transplant Recipient

Keywords

Organ transplant recipient, Skin cancer, Skin dysplasia, Human papillomavirus, HPV-related dysplasia, HPV-related cancer, HPV

Brief summary

Solid organ transplant recipients (OTRs) receive lifelong immunosuppressive therapy, which puts them at increased risk of cutaneous and mucosal cancers. In particular, OTRs have increased risk of skin cancer and cancers caused by human papillomavirus (HPV), including cervical cancer and oropharyngeal cancer. There is currently limited knowledge on risk factors for HPV infection and skin cancer in OTRs, and limited knowledge on the natural history of HPV infection and cervical neoplasia in OTRs compared with immunocompetent controls. With a continuously increasing number of OTRs, there is a growing need to improve our understanding of the long-term reactions to immunosuppression. The overall aim of this study is to investigate long term effects of immunosuppression on cutaneous and mucosal epithelium in Danish OTRs, including the risk of skin dysplasia and skin cancer, cervical and oral HPV infection and HPV-related dysplasia and cancer in OTRs. This study will be designed as a prospective observational cohort study based on clinical data and data from nationwide Danish registries. A total of 600 female OTRs, 300 male OTRs and 600 female controls will be included from Danish dermatology departments. The study aims to provide knowledge relevant for improving prevention of skin- and HPV-related cancers in OTRs, including personalized screening recommendations according to individual patient risk.

Detailed description

AIMS The specific research objectives of this study are: 1. To investigate the overall and type-specific prevalence, incidence and persistence of cervical HPV infection in OTRs compared to immunocompetent controls. 2. To investigate the overall and type-specific prevalence of oral HPV infection in female OTRs compared to immunocompetent controls. 3. To determine the role of lifestyle and clinical factors for the occurrence of cervical and oral HPV infection in female OTRs. 4. To investigate the prevalence and incidence of HPV-related dysplasia and cancer in female OTRs compared with immunocompetent controls. 5. To determine the role of lifestyle, clinical and organ transplantation-related factors for the prevalence and incidence of skin dysplasia in OTRs. 6. To investigate associations between skin dysplasia and prevalence of cervical HPV infection and VZV infection in OTRs. METHODS The study will be designed as a clinical prospective cohort study. A total of 600 female OTRs, 300 male OTRs and 600 female immunocompetent controls will be included from the Departments of Dermatology at Bispebjerg, Gentofte and Roskilde Hospitals, Denmark. The following data will be collected from OTRs: * At baseline: Questionnaire, dermatologic skin assessment, assessment of skin photodamage (only OTRs recruited from Bispebjerg Hospital), medical record information, cervico-vaginal HPV self-sample test (women only), oral sample for HPV test (women only), blood sample for future research, blood sample for vitamin D test (only OTRs recruited from Bispebjerg Hospital). * After 6 months: New blood sample for vitamin D test (only OTRs recruited from Bispebjerg Hospital). * After 12 months: New cervico-vaginal HPV self-sample test (women only). The following data will be collected from female immunocompetent controls: * At baseline: Questionnaire, cervico-vaginal HPV self-sample test, oral sample for HPV test. * After 12 months: New cervico-vaginal HPV self-sample test. A REDCap database will be established for study data. The RedCap database is encrypted and accessed electronically with personal user-ID and password. The study population will be linked with nationwide Danish registries and clinical databases. From these registers information on cases of precancerous lesions and cancer; other HPV-related conditions; participation in HPV vaccination and cervical cancer screening; co-morbidities, pregnancies, births and medicine use; socio-demographic characteristics; and emigration and death of women in the study population will be obtained. Registry linkage will be performed for up to 15 years after end of study.

Interventions

OTHERNo intervention

The study is an observational study without intervention.

Sponsors

Danish Cancer Society
CollaboratorOTHER
Zealand University Hospital
CollaboratorOTHER
Vejle Hospital
CollaboratorOTHER
Herlev and Gentofte Hospital
CollaboratorOTHER
Rigshospitalet, Denmark
CollaboratorOTHER
Merete Haedersdal
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for OTRs: * Patients aged ≥18 years * Solid organ transplantation recipients, i.e. kidney-, liver-, lung-, and heart transplant recipients * Stable immunosuppressive treatment for ≥3 months * No signs of acute graft rejection * Patients who reside in Denmark * Informed written consent obtained

Exclusion criteria

for OTRs: * Patients with concomitant bone marrow transplantation * Full hysterectomy Inclusion Criteria for Control group: * Able patients aged ≥18 years * No known immunosuppressive therapy or -condition * Patients who reside in Denmark * Informed written consent obtained

Design outcomes

Primary

MeasureTime frameDescription
Difference in prevalence, incidence and persistence of cervical HPV infection in female OTRs compared to immunocompetent controls.Evaluated at baseline and month 12Number of women with cervical HPV infection measured by PCR test.

Secondary

MeasureTime frameDescription
Correlations between lifestyle factors, clinical factors and occurrence of cervical HPV infection in female OTRs.Evaluated at baselineLifestyle factors determined by questionnaire. Clinical factors from medical records. Number of women with cervical HPV infection measured by PCR test.
Correlations between lifestyle factors, clinical factors and occurrence of oral HPV infection in female OTRs.Evaluated at baselineLifestyle factors determined by questionnaire. Clinical factors from medical records. Number of women with oral HPV infection measured by PCR test.
Difference in prevalence and incidence of HPV-related dysplasia and cancer in female OTRs compared to immunocompetent controls.Evaluated at baseline and during up to 15 years after baseline.Number of women with HPV-related dysplasia and HPV-related cancer from registries using registry linkage.
Correlations between lifestyle factors, clinical factors and prevalence of skin dysplasia and cancer in OTRs.Evaluated at baselineLifestyle factors determined by a questionnaire. Clinical factors from medical records. Skin dysplasia and skin cancer assessed by clinical evaluation and by non-invasive imaging.
Difference in prevalence of oral HPV infection in female OTRs compared to immunocompetent controls.Evaluated at baselineNumber of women with oral HPV infection measured by PCR test.
Correlations between skin pigmentation, facial solar lentigines and prevalence of skin dysplasia and cancer in OTRs.Evaluated at baselineSkin pigmentation measured with skin reflectance. Facial solar lentigines measured by photographs. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging.
Correlation between prevalence of cervical HPV infection and prevalence of skin dysplasia and cancer in OTRs.Evaluated at baselineNumber of women with cervical HPV infection measured by PCR test. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging.
Correlations between history of herpes zoster, prevalence of cervical HPV infection and prevalence of skin dysplasia and cancer in OTRs.Evaluated at baselineNumber of women with history of herpes zoster determined by questionnaire. Number of women with cervical HPV infection measured by PCR test. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging.
Difference in prevalence and incidence of skin cancer in female OTRs compared to immunocompetent controls.Evaluated at baseline and during up to 15 years after baseline.Number of women with skin cancer from registries using registry linkage
Correlation between Vitamin D and prevalence of skin dysplasia and cancer in OTRs.Evaluated at baselineVitamin D from blood sample analysis. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging.

Countries

Denmark

Contacts

Primary ContactLene Rask
lene.rask.01@regionh.dk+45 23359940

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026